Skip to main content
. 2019 Jan 31;139(15):1798–1812. doi: 10.1161/CIRCULATIONAHA.118.036053

Figure 7.

Figure 7.

Continuous POL5551 infusion mobilizes regulatory T cells but prevents their cardiac recruitment and therapeutic effects. A, Expression levels of C-X-C motif chemokine ligand 12 (CXCL12) in the infarcted region at various time points after myocardial infarction (MI) or sham operation (day 7) as determined by reverse-transcription quantitative polymerase chain reaction. Five to 9 mice per group. **P<0.01, ***P<0.001 vs sham (1-way ANOVA with Dunnett post hoc test). B, Experimental setup for C and D. MI was induced in DEREG mice. POL5551 (POL) or vehicle only (control [Con]) was injected intraperitoneally 2 and 4 days after MI or infused subcutaneously starting 2 days after MI. C, CD4+ Foxp3+/eGFP+ regulatory T (Treg) cell numbers in the peripheral blood and (D) in the infarcted region at 4 days + 2 hours after MI. Four to 5 mice per group. E, Experimental setup for F through I. MI was induced in wild-type (WT) mice. POL5551 or vehicle only (Con) was injected intraperitoneally 2, 4, 6, and 8 days after MI or infused subcutaneously for 7 days starting 2 days after MI. 5 to 7 mice per group. Echo indicates echocardiography. F, Fluorescein-labeled isolectin B4 (IB4)+ capillary density in the infarct border zone 28 days after MI. CM indicates cardiomyocyte. G, Scar size 28 days after MI. LV indicates left ventricle. H, LV end-diastolic area (LVEDA) and LV end-systolic area (LVESA) as determined by echocardiography 28 days after MI. LVEDA: P<0.05, POL5551 vs vehicle-only boluses; LVESA: P<0.001, POL5551 vs vehicle-only boluses (2-independent-sample t tests). I, Fractional area change (FAC). *P<0.05 (2-independent-sample t tests).